Acute hepatitis C in a patient receiving etanercept

According to the literature, the use of tumor necrosis factor (TNF) inhibitors in patients with chronic hepatitis C infection is safe and effective. There have been no reports, however, of primary infection with the hepatitis C virus during treatment with a biologic agent. We report the case of a pa...

Full description

Saved in:
Bibliographic Details
Published in:Actas dermo-sifiliográficas (English ed.) 2013-04, Vol.104 (3), p.239-241
Main Authors: Armengot-Carbó, M, Velasco, M, Giner, R, Gimeno, E
Format: Article
Language:eng ; spa
Subjects:
Acute Disease
Etanercept
Hepatitis C - chemically induced
Humans
Immunoglobulin G - adverse effects
Male
Middle Aged
Receptors, Tumor Necrosis Factor - antagonists & inhibitors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:According to the literature, the use of tumor necrosis factor (TNF) inhibitors in patients with chronic hepatitis C infection is safe and effective. There have been no reports, however, of primary infection with the hepatitis C virus during treatment with a biologic agent. We report the case of a patient with long-standing moderate to severe psoriasis who developed acute hepatitis C while being treated with etanercept. Biologic therapy was continued and the infection was successfully treated with pegylated interferon, which achieved a sustained virologic response. Etanercept did not have a negative impact on disease outcome or on response to antiviral treatment.
ISSN:1578-2190
DOI:10.1016/j.ad.2011.08.014